Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Conditions
Brief summary
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Detailed description
PRIMARY OBJECTIVES: I. To determine the recommended phase 2 dose of SCH727965 administered as a 4-hour infusion every other week in patients with advanced malignant melanoma. (Phase I) II. To determine the 1-year overall survival of patients with malignant melanoma treated with SCH727965 at the dose and schedule derived in the phase 1 part of the study. (Phase II) SECONDARY OBJECTIVES: I. To characterize the safety profile and toxicities of SCH727965 administered as a 4-hour infusion every other week. II. To determine the pharmacokinetics of SCH727965 administered as a 4-hour infusion every other week. III. To determine the proportion of patients with malignant melanoma who are alive without progression of disease 6 months after beginning treatment with SCH727965 at the dose and schedule derived in the phase 1 part of the study. IV. To determine the objective response rate to SCH727965 of patients with malignant melanoma enrolled to part 2 of the study. V. To document cdk2, combined cdk2/1 and cdk9 inhibition in surrogate tissues and tumor. VI. To correlate the degree of change of pharmacodynamic parameters in post-treatment compared to pre-treatment samples with clinical outcome. VII. To correlate the degree of change of parameters defining cdk2, cdk2/1 and cdk9 inhibition with pharmacokinetic parameters. VIII. To correlate pre-treatment cdk2 levels with the degree of change of parameters measuring cdk2 inhibition. IX. To correlate pre-treatment cdk2 levels with clinical outcome. X. To correlate tumor p53 status with clinical outcome. OUTLINE: This is a phase I dose-escalation study followed by a phase II study. Patients receive dinaciclib IV over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
Interventions
DRUGdinaciclib
Given IV
OTHERpharmacological study
Correlative studies
OTHERlaboratory biomarker analysis
Correlative studies
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically confirmed, unresectable stage III or stage IV malignant melanoma * ECOG performance status =\< 1 * Absolute neutrophil count \>= 1.5 x 10\^9/L * Platelets \>= 100 x 10\^9/L * Total bilirubin within normal institutional limits * AST(SGOT)/ALT(SGPT =\< 1.5 x institutional upper limit of normal * Creatinine =\< 1.5 mg/dl OR * Creatinine clearance \>= 50 mL/min for patients with creatinine levels above institutional normal * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately * Eligible patients must agree to pre- and post-treatment biopsies of normal skin; in the phase 1 part of the study, patients with cutaneous disease or accessible lymph nodes must also agree to pre- and post-treatment tumor biopsies; in the phase 2 part of the study, tumor biopsies are required of the first 20 patients enrolled who have cutaneous disease or accessible lymph nodes * Patients enrolled to the Phase 2 portion of the study must have measurable disease by RECIST criteria * Ability to understand and the willingness to sign a written informed consent document
Exclusion criteria
* Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier * Patients may not be receiving any other investigational agents * Patients with active CNS metastases are excluded; patients with a history of CNS metastases that have been treated must be stable for 4 weeks after completion of treatment, with image documentation required; patients must not be taking enzyme-inducing anticonvulsants and must be either off steroids or be receiving a stable dose of steroids * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with SCH727965 * HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with SCH727965; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated * Patients with other currently active malignancies are excluded, except those with an in-situ cancer or basal or squamous cell carcinoma of the skin * In the phase 2 part of the study, patients who have received prior investigational treatment with a cdk inhibitor are excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase-2 Dose of SCH727965 | 14 days | Due to difficult accrual to the trial, enrollment was ended early without determination of an MTD. |
| Percentage of Patients Alive (Phase II) | Up to 1 year | Due to difficult accrual to the trial, enrollment was ended early without entering into Phase II |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free Survival | Up to 6 months |
Countries
United States
Participant flow
Recruitment details
Subjects were screened and enrolled at one site in the US, Dana Farber Cancer Institute.
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Dinaciclib) Dose Level 1 Patients receive dinaciclib at Dose Level 1 (10 mg/m2 IV) over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
dinaciclib: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies | 5 |
| Treatment (Dinaciclib) Dose Level 2 Patients receive dinaciclib at Dose Level 2 (20 mg/m2 IV) over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
dinaciclib: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies | 3 |
| Treatment (Dinaciclib) Dose Level 3 Patients receive dinaciclib at Dose Level 3 (30 mg/m2 IV) over 4 hours on day 1. Courses repeat every 14 days in the absence of disease progression and unacceptable toxicity.
dinaciclib: Given IV pharmacological study: Correlative studies laboratory biomarker analysis: Correlative studies | 4 |
| Total | 12 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 |
|---|---|---|---|---|
| Follow up/Survival | Withdrawal by Subject | 1 | 0 | 0 |
Baseline characteristics
| Characteristic | Treatment (Dinaciclib) Dose Level 1 | Treatment (Dinaciclib) Dose Level 2 | Treatment (Dinaciclib) Dose Level 3 | Total |
|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 1 Participants | 0 Participants | 2 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 2 Participants | 4 Participants | 10 Participants |
| Sex: Female, Male Female | 2 Participants | 2 Participants | 1 Participants | 5 Participants |
| Sex: Female, Male Male | 3 Participants | 1 Participants | 3 Participants | 7 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 5 / 5 | 3 / 3 | 4 / 4 |
| other Total, other adverse events | 5 / 5 | 3 / 3 | 4 / 4 |
| serious Total, serious adverse events | 5 / 5 | 3 / 3 | 4 / 4 |
Outcome results
Primary
Percentage of Patients Alive (Phase II)
Due to difficult accrual to the trial, enrollment was ended early without entering into Phase II
Time frame: Up to 1 year
Population: Due to difficult accrual to the trial, enrollment was ended early without entering into Phase II
Primary
Recommended Phase-2 Dose of SCH727965
Due to difficult accrual to the trial, enrollment was ended early without determination of an MTD.
Time frame: 14 days
Population: Due to difficult accrual to the trial, enrollment was ended early without determination of an MTD.
Secondary
Progression-free Survival
Time frame: Up to 6 months
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Treatment (Dinaciclib) | Progression-free Survival | Progressive Disease | 1 participants |
| Treatment (Dinaciclib) | Progression-free Survival | Stable Disease | 2 participants |
| Treatment (Dinaciclib) | Progression-free Survival | Unevaluable | 2 participants |
| Treatment (Dinaciclib) Dose Level 2 | Progression-free Survival | Progressive Disease | 3 participants |
| Treatment (Dinaciclib) Dose Level 2 | Progression-free Survival | Stable Disease | 0 participants |
| Treatment (Dinaciclib) Dose Level 2 | Progression-free Survival | Unevaluable | 0 participants |
| Treatment (Dinaciclib) Dose Level 3 | Progression-free Survival | Stable Disease | 0 participants |
| Treatment (Dinaciclib) Dose Level 3 | Progression-free Survival | Unevaluable | 0 participants |
| Treatment (Dinaciclib) Dose Level 3 | Progression-free Survival | Progressive Disease | 4 participants |